Treatment of retinal angiomatous proliferation lesions due to age-related macular degeneration with ranibizumab (Lucentis®) and photodynamic therapy with verteporfin (Visudyne®) - LUPRA

Department of Ophthalmology, Medical University of Graz0 个研究点目标入组 15 人开始时间: 2008年4月7日最近更新: 2016年11月7日

适应症

试验速览

暂无简介。

•Patients who at baseline
•have a best corrected visual acuity (BCVA) letter score in the study eye between 73-24 (approximately 20/40 to 20/320) using an ETDRS chart measured at 4 meters or Snellen equivalent
•have a RAP lesion in the study eye with the following characteristics as determined by fluorescein and indocyanine green angiography:
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•any other form of AMD or of neovascular maculopathy, including pathologic myopia, angioid streaks, infectious or inflammatory chorioretinal diseases, ocular tumors, prior radiation therapy, hereditary disorders, or trauma.
•Patients who have a BCVA of < 33 letters (approximately 20/200) in both eyes
•Prior treatment in the study eye with verteporfin, external-beam radiation therapy, vitrectomy, submacular surgery, other surgical intervention for AMD, or transpupillary thermotherapy

发起方

Department of Ophthalmology, Medical University of Graz